Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-102 in FGFR2b-overexpressing advanced gastric or gastroesophageal junction cancer
2023-505458-16-00Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Bemarituzumab + nivolumab + chemotherapy with Placebo + nivolumab + chemotherapy (2 arms). Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 3 more. Started Sep 2022; status: completed.
02
Drugs
bemarituzumabnivolumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-505458-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505458-16-00.